Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
TOKYO, August 18, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the in-house discovered and developed orexin receptor antagonist … Read More